skin cancer
Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic
The company's DecisionDx-SCC is meant to predict risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.
The company said it is developing a new genomic test to predict therapeutic response in patients with inflammatory skin conditions.
Castle Biosciences Q1 Revenues Up 31 Percent
The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent.
Eye Color GWAS Leads to 50 New Loci, Underscoring Trait's Complexity
A genome-wide association study in almost 193,000 Europeans led to 61 eye color-related loci, some of which also influence iris pigmentation of Asian individuals.
Castle Biosciences Q4 Revenues Down 2 Percent
The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter.